Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors.

Identification of tumors harboring an overall active immune phenotype may help for selecting patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small cell lung cancer (NSCLC) who may benefit from immunotherapies. In this context, we generated targeted gene expression profiles in three and two independent cohorts of patients with HNSCC or NSCLC respectively, treated or not by PD-1/PD-L1 inhibitors. Notably, we generated two datasets including 102 and 82 patients with HNSCC or NSCLC treated with PD-1/PD-L1 inhibitors. Clinical information, including detailed survival raw data, is available for each patient, allowing to test association between gene expression data and patient survival (overall and progression-free survival). Moreover, we also generated gene expression datasets of 27 paired HNSCC samples from diagnostic biopsies and versus surgically resected specimens as well as 33 paired HNSCC samples at initial diagnosis (untreated) and at recurrence. Those datasets may allow to test the stability of a given biomarker across paired samples.
Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: PS is a member of HTG Diagnostics Scientific Advisory Board and receives research grants from HTG Diagnostics, Inivata, ArcherDx, Bristol-Myers Squibb, Roche Molecular Diagnostics, Roche, AstraZeneca, Novartis, Bristol-Myers Squibb Foundation and Illumina; JF reports grants, personal fees and non-financial support from Bristol-Myers Squibb, personal fees and non-financial support from MSD, personal fees from Merck, personal fees and non-financial support from Astrazeneca, personal fees from Rakuten, personal fees from Biogen and personal fees from Innate Pharma; SL received advisory board honoraria from AbbVie, AstraZeneca, Bayer, Bristol-Myers Squibb, Merck Sharp and Dohme, Takeda, Roche/Genentech; FG reports personal grants consultancy for Roche, AstraZeneca, and payments for development of educational presentations for Roche, Servier, Amgen, Merck. All remaining authors have declared no conflicts of interest.
(© 2022 The Authors.)